The Sunday Age / Sydney Morning Herald : Patient route to healthy profits
26 February 2012
David Potts details how biotechnology companies are increasing in value and defying market conditions. He profiles 6 of the top buys, including Starpharma.
Flushed with funds after a capital raising at the end of last year, with 100 patents and some of the world's biggest drug companies as partners you couldn't pick a better name for Starpharma.
But its real beauty is that it doesn't have to invent new drugs - it makes existing ones work better, which also means it's not dependent on a specific one.
Go to the article (external link)
This document contains Forward Looking Statements